AI-Powered Programmable Drug Delivery
Mana.bio (mana.bio) earns a Brand Analyzer score of 68 out of 100, placing it in the Developing tier among Healthcare brands, Technology brands. Among 2305 Healthcare brands analyzed, Mana.bio ranks in the 49th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 76/100, Visual Identity 90/100, Messaging Clarity 100/100, Trust Foundation 47/100, AI Discoverability 85/100, Brand Authority 23/100.
Mana.bio is an AI-based drug delivery startup that applies machine learning and nanotechnology to develop programmable drug delivery systems. The company specializes in lipid nanoparticles (LNPs) and focuses on RNA-based therapeutics, DNA therapeutics, and vaccines. Its mission is to disrupt the drug delivery space by enabling more precise, programmable delivery mechanisms for gene therapy applications, serving biotech researchers and pharmaceutical companies.
| Brand Name | Mana.bio |
|---|---|
| Domain | mana.bio |
| Industry | Healthcare, Technology |
| Main Competitors | Intellia Therapeutics, Precision BioSciences, Alnylam Pharmaceuticals, Moderna, Arctus Biotherapeutics, Beam Therapeutics |
Moz Domain Authority 23/100 vs category average 29 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Mana.bio is an AI-based drug delivery startup specializing in programmable drug delivery and gene therapy, with a focus on lipid nanoparticles (LNPs), RNA-based therapeutics, DNA t…" (Meta description: 28 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 2 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, Instagram, GitHub; no detected presence on X (Twitter), Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Mana.bio scores 34/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Mana.bio has a weak AI-visibility profile at 34/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is trust (49/100) and its weakest is visibility (17/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and a low Moz Domain Authority of 23/100.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Mana.bio's main competitors include Intellia Therapeutics, Precision BioSciences, Alnylam Pharmaceuticals, Moderna, Arctus Biotherapeutics. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Mana.bio official site
Popular alternatives to Mana.bio include Intellia Therapeutics, Precision BioSciences, Alnylam Pharmaceuticals, Moderna, Arctus Biotherapeutics. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Mana.bio official site
Mana.bio has limited AI-search visibility, scoring 34/100 on Brand Analyzer's AI visibility composite (visibility 17, trust 49, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Mana.bio official site
Mana.bio is an AI-based drug delivery startup that specializes in programmable drug delivery and gene therapy. The company operates at the intersection of machine learning and nanotechnology, with a particular focus on lipid nanoparticles (LNPs) as a delivery mechanism. It targets applications in RNA-based therapeutics, DNA therapeutics, and vaccines, positioning itself as an innovator in the programmable drug delivery space.
Sources: Mana.bio official site
Mana.bio and Intellia Therapeutics are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Mana.bio official site
Mana.bio develops programmable drug delivery systems using artificial intelligence and nanotechnology. Specifically, the company works with lipid nanoparticles (LNPs) to enable targeted delivery of RNA-based therapeutics, DNA therapeutics, and vaccines. Its mission is to disrupt the drug delivery space by leveraging machine learning to optimize and program how therapeutics are delivered within the body, with a strong focus on gene therapy applications.
Sources: Mana.bio official site
Mana.bio scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Mana.bio official site
Mana.bio can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Mana.bio official site
Based on available information, Mana.bio's offerings center on programmable drug delivery solutions utilizing lipid nanoparticles (LNPs). These are applied across RNA-based therapeutics, DNA therapeutics, gene therapy, and vaccines. The company uses AI and nanotechnology as core enabling technologies for these delivery systems. Specific named products or commercial product lines are not detailed in the available facts.
Sources: Mana.bio official site
Mana.bio's target audience includes biotech researchers, pharmaceutical companies, and gene therapy developers. These users likely engage with Mana.bio's technology to advance their own therapeutic programs, leveraging its AI-driven lipid nanoparticle delivery platforms for applications in RNA therapeutics, DNA therapeutics, and vaccine development.
Sources: Mana.bio official site
Mana.bio is known for its AI-driven approach to programmable drug delivery, with a specialization in lipid nanoparticles (LNPs). The company is recognized for applying machine learning and nanotechnology to advance gene therapy, RNA-based therapeutics, DNA therapeutics, and vaccines. Its positioning as an AI-based innovator in the drug delivery space distinguishes it within the biotech and pharmaceutical sectors.
Sources: Mana.bio official site
Ranked closest to Mana.bio: Madaket Health (68/100), Legal Record Desk (68/100), Medsender (68/100), Medtech Global (68/100).
A step up - brands to learn from: Zipari by mPulse (71/100), Zaina AI (71/100).
Category leader: Dassault Systèmes (95/100).